新诺威（300765.SZ）近日发布公告，公司总经理姚兵因工作调整原因辞任总经理职务，辞职后将继续担任公司董事及其他管理职务。经董事会提名与审议，决定由戴龙接任公司总经理，全面负责公司日常经营管理工作。戴龙在公司任职多年，具有丰富的医药行业经验与战略管理能力，其上任有望进一步推动公司核心业务发展与创新转型。新诺威作为石药集团旗下重要的医药健康板块上市公司，此举被视为公司优化治理结构、深化战略布局的重要举措，市场对其未来战略延续性与业务增长保持积极预期。
Nova Nordic (300765.SZ) recently announced that Yao Bing has resigned as General Manager due to work adjustment reasons. He will continue to serve as a director and hold other management positions within the company. Following nomination and review by the board of directors, Dai Long has been appointed as the new General Manager, taking full responsibility for the company’s daily operations and management. With extensive experience in the pharmaceutical industry and strategic management capabilities gained through years of service at the company, Dai Long’s appointment is expected to further drive the development and innovative transformation of Nova Nordic’s core businesses. As a key listed company in the health sector under Sino Pharmaceutical Group, this move is seen as an important step in optimizing corporate governance and deepening strategic planning, with market observers maintaining positive expectations for the company’s future continuity and business growth.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/24406.html